Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
Journal of Biomolecular Screening
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1087057108326081v1
13/10/1025    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Patnaik, D.
Right arrow Articles by Higgins, J. M.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patnaik, D.
Right arrow Articles by Higgins, J. M.G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Identification of Small Molecule Inhibitors of the Mitotic Kinase Haspin by High-Throughput Screening Using a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer Assay

Debasis Patnaik

Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Jun Xian

Partners Center for Drug Discovery, Brigham and Women's Hospital, Harvard NeuroDiscovery Center, Cambridge, Massachusetts

Marcie A. Glicksman

Partners Center for Drug Discovery, Brigham and Women's Hospital, Harvard NeuroDiscovery Center, Cambridge, Massachusetts, Laboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital, Harvard NeuroDiscovery Center, Cambridge, Massachusetts

Gregory D. Cuny

Partners Center for Drug Discovery, Brigham and Women's Hospital, Harvard NeuroDiscovery Center, Cambridge, Massachusetts, Laboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital, Harvard NeuroDiscovery Center, Cambridge, Massachusetts

Ross L. Stein

Partners Center for Drug Discovery, Brigham and Women's Hospital, Harvard NeuroDiscovery Center, Cambridge, Massachusetts, Laboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital, Harvard NeuroDiscovery Center, Cambridge, Massachusetts

Jonathan M.G. Higgins

Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, jhiggins{at}rics.bwh.harvard.edu

Haspin/Gsg2 is a kinase that phosphorylates histone H3 at Thr-3 (H3T3ph) during mitosis. Its depletion by RNA interference results in failure of chromosome alignment and a block in mitosis. Haspin, therefore, is a novel target for development of antimitotic agents. We report the development of a high-throughput time-resolved fluorescence resonance energy transfer (TR-FRET) kinase assay for haspin. Histone H3 peptide was used as a substrate, and a europium-labeled H3T3ph phosphospecific monoclonal antibody was used to detect phosphorylation. A library of 137632 small molecules was screened at Km concentrations of ATP and peptide to allow identification of diverse inhibitor types. Reconfirmation of hits and IC 50 determinations were carried out with the TR-FRET assay and by a radiometric assay using recombinant histone H3 as the substrate. A preliminary assessment of specificity was made by testing inhibition of 2 unrelated kinases. EC 50 values in cells were determined using a cell-based ELISA of H3T3ph. Five compounds were selected as leads based on potency and chemical structure considerations. These leads form the basis for the development of specific inhibitors of haspin that will have clear utility in basic research and possible use as starting points for development of antimitotic anticancer therapeutics. (Journal of Biomolecular Screening 2008:1025-1034)

Key Words: antimitotics • chromatin • haspin • kinase • time-resolved fluorescence resonance energy transfer

This version was published on December 1, 2008

Journal of Biomolecular Screening, Vol. 13, No. 10, 1025-1034 (2008)
DOI: 10.1177/1087057108326081


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Eswaran, D. Patnaik, P. Filippakopoulos, F. Wang, R. L. Stein, J. W. Murray, J. M. G. Higgins, and S. Knapp
Structure and functional characterization of the atypical human kinase haspin
PNAS, December 1, 2009; 106(48): 20198 - 20203.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
F. Villa, P. Capasso, M. Tortorici, F. Forneris, A. de Marco, A. Mattevi, and A. Musacchio
Crystal structure of the catalytic domain of Haspin, an atypical kinase implicated in chromatin organization
PNAS, December 1, 2009; 106(48): 20204 - 20209.
[Abstract] [Full Text] [PDF]